125 related articles for article (PubMed ID: 764975)
21. Oral bacille Calmette Guérin immunostimulation in malignant melanoma.
MacGregor AB; Falk RE; Landi S; Ambus U; Langer B
Surg Gynecol Obstet; 1975 Nov; 141(5):747-54. PubMed ID: 1105837
[TBL] [Abstract][Full Text] [Related]
22. [Results of immunochemotherapy in malignant melanoma].
Duchková H; Richter J; Kubíková M; Peska J; Ragan J; Vohryzková E; Hrivnáková J; Kvasnicka J
Cesk Dermatol; 1980 Aug; 55(4):277-80. PubMed ID: 7407970
[No Abstract] [Full Text] [Related]
23. Immunology and immunotherapy of human-malignant melanoma: historic review and perspectives for the future.
Gutterman JU; Mavligit G; Reed R; Richman S; McBride CE; Hersh EM
Semin Oncol; 1975 Jun; 2(2):155-74. PubMed ID: 790574
[No Abstract] [Full Text] [Related]
24. BCG immunotherapy in previously treated malignant melanoma patients.
Mujagić H; Kolarić K; Malenica B; Nola P
Biomedicine; 1979 Jun; 30(2):95-102. PubMed ID: 476270
[TBL] [Abstract][Full Text] [Related]
25. [Development in the immunotherapy of malignant melanoma].
Tritsch H
Hautarzt; 1976 Jan; 27(1):1-7. PubMed ID: 767300
[TBL] [Abstract][Full Text] [Related]
26. Effect of bacillus Calmette-Guerin immunotherapy on tumor antigen-induced lymphocyte-stimulated protein synthesis in melanoma patients.
Roth JA; Golub SH; Holmes EC; Morton DL
Surgery; 1975 Jul; 78(1):66-75. PubMed ID: 1138401
[TBL] [Abstract][Full Text] [Related]
27. Monitoring immunotherapy with Bacillus Calmette-Guérin by antibody titer.
Wile AG; Sparks FC; Morton DL
Cancer Res; 1977 Jul; 37(7 Pt 1):2251-6. PubMed ID: 324610
[TBL] [Abstract][Full Text] [Related]
28. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S
J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507
[TBL] [Abstract][Full Text] [Related]
29. BCG, levamisole and transfer factor in the treatment of cancer.
Spitler LE
Prog Exp Tumor Res; 1980; 25():178-92. PubMed ID: 6986631
[No Abstract] [Full Text] [Related]
30. Malignant melanoma.
Spitler LE
J Invest Dermatol; 1976 Sep; 67(3):435-41. PubMed ID: 787436
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of tuberculin and BCG immunoreactivity in stage I high-risk malignant melanoma (EORTC protocol 18781).
Henz BM; Macher E; Bröcker EB; Suciu S; Steerenberg PA; Jung E; Rümke P
Dermatology; 1996; 193(2):105-9. PubMed ID: 8884144
[TBL] [Abstract][Full Text] [Related]
32. Randomized trial of adjuvant therapy for "high risk" primary malignant melanoma.
Wood WC; Cosimi AB; Carey RW; Kaufman SD
Surgery; 1978 Jun; 83(6):677-81. PubMed ID: 644461
[TBL] [Abstract][Full Text] [Related]
33. A randomized trial of adjuvant chemotherapy and immunotherapy in Stage I and Stage II cutaneous melanoma. An interim report.
Sterchi JM; Wells HB; Case LD; Spurr CL; White DR; Richards F; Muss HB; Jackson DV; Stuart JJ; Cooper MR
Cancer; 1985 Feb; 55(4):707-12. PubMed ID: 3967167
[TBL] [Abstract][Full Text] [Related]
34. Pulmonary manifestations in patients with malignant melanoma during BCG immunotherapy. A preliminary report.
Bilgi C; Brown NE; McPherson TA; Lentle B
Chest; 1979 Jun; 75(6):685-7. PubMed ID: 436519
[TBL] [Abstract][Full Text] [Related]
35. Mycobacterium bovis BCG in metastatic melanoma therapy.
Benitez MLR; Bender CB; Oliveira TL; Schachtschneider KM; Collares T; Seixas FK
Appl Microbiol Biotechnol; 2019 Oct; 103(19):7903-7916. PubMed ID: 31402426
[TBL] [Abstract][Full Text] [Related]
36. [Studies on the immune status of melanoma patients: cell-mediated immune reactions in intracutaneous and epicutaneous tests in the lymphocyte transformation test and the leukocyte-migration inhibition test before and during BCG immunotherapy (author's transl)].
Knopf B; Wätzig V; Knöll B
Arch Geschwulstforsch; 1978; 48(8):722-8. PubMed ID: 753194
[TBL] [Abstract][Full Text] [Related]
37. Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional
Da Gama Duarte J; Parakh S; Andrews MC; Woods K; Pasam A; Tutuka C; Ostrouska S; Blackburn JM; Behren A; Cebon J
Front Immunol; 2018; 9():411. PubMed ID: 29552014
[TBL] [Abstract][Full Text] [Related]
38. Chemoimmunotherapy increases the lymphocyte reactivity of melanoma patients.
Berkelhammer J; Mastrangelo MJ; Bellet RE; Berd D; Prehn RT
Eur J Cancer (1965); 1979 Feb; 15(2):197-204. PubMed ID: 436896
[No Abstract] [Full Text] [Related]
39. Mumps virus and BCG vaccine in metastatic melanoma.
Minton JP
Arch Surg; 1973 Apr; 106(4):503-6. PubMed ID: 4572347
[No Abstract] [Full Text] [Related]
40. Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma.
Lipton A; Harvey HA; Lawrence B; Gottlieb R; Kukrika M; Dixon R; Graham W; Miller S; Heckard R; Schelzel D; White DS
Cancer; 1983 Jan; 51(1):57-60. PubMed ID: 6821809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
